Tumor infiltrating regulatory T cells: tractable targets for immunotherapy.
Several studies have linked tumor-infiltration by regulatory T cells with poor patient outcome. Targeting the mechanisms by which regulatory T cells traffic to and persist in the tumor may circumvent tumor immune-escape by de-restricting T cell-mediated cytotoxicity. In this review, we describe the principle axes that govern regulatory T cell migration and the mechanisms that underpin their immunosuppressive activity in cancer. Inhibiting either the migration or function of regulatory T cells may enhance host-anti-cancer immune responses and as such are attractive and tractable targets for therapeutic intervention.
Khan
Adnan R
AR
Doctoral Training Centre for Targeted Therapeutics, School of Pharmacy, University of Nottingham, Nottingham, UK.
Dovedi
Simon J
SJ
Wilkinson
Robert W
RW
Pritchard
David I
DI
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000037:antagonists & inhibitors; D006801:Humans; D007165:Immunosuppression Therapy; D007167:Immunotherapy / Q000639:trends; D016246:Lymphocytes, Tumor-Infiltrating / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D019139:Tumor Escape
D000970:Antineoplastic Agents; D016207:Cytokines; D011505:Protein-Tyrosine Kinases